Refine Search

Search Results -

Term	Documents
@PY	35080757
(23 AND (@PY < "1986")).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0
(L23 AND @PY<1986).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L24

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Thursday, May 19, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L24	L23 and @py<1986	0	L24
L23	Factor VIII light chains same heavy chain	40	L23
L22	L19 and A domain and C domain	0	L22
L21	L20 and domain	0	L21
L20	L19 and A and C	18	L20
L19	L18 and @py<1986	18	L19
L18	human Factor VIII	738	L18
L17	L8 and @py<1986	0	L17
L16	L9 and @py<1986	0	L16
L15	L10 and @py<1986	0	L15
L14	L9 and py<1986	241	L14

L13	L12 and @py<1986	0	L13
L12	L11 and L10	227	L12
L11	L9 and plasmid	227	L11
L10	L9 and vector	236	L10
L9	L8 and polynucleotide	241	L9
L8	Factor VIII same polypeptide same express$	425	L8
L7	Factor VIIi ame polypeptide same express$	0	L7
L6	L5 and @py<1986	5	L6
L5	L4 and expression	3349	L5
L4	L3 and plasmid	3452	L4
L3	L2 and A and C	7011	L3
L2	Factor VIII	7736	L2
L1	US 4868112	3	L1

END OF SEARCH HISTORY

FILE 'PROMT' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'PS' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 14:11:35 ON 19 MAY 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 14:11:35 ON 19 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:11:35 ON 19 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 14:11:35 ON 19 MAY 2005
COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s Factor VIII
  25 FILES SEARCHED...
  31 FILES SEARCHED...
  54 FILES SEARCHED...
L1   107562 FACTOR VIII

=> s domain A and domain C
  13 FILES SEARCHED...
  22 FILES SEARCHED...
  25 FILES SEARCHED...
  32 FILES SEARCHED...
  50 FILES SEARCHED...
  62 FILES SEARCHED...
  66 FILES SEARCHED...
  69 FILES SEARCHED...
L2   2583 DOMAIN A AND DOMAIN C

=> s L1 and L2
  56 FILES SEARCHED...
L3   60 L1 AND L2

```
=> s vector
SYSTEM LIMITS EXCEEDED - SEARCH ENDED
  38 FILES SEARCHED...
The search profile you entered was too complex or gave too many
answers.  Simplify or subdivide the query and try again.  If you have
exceeded the answer limit, enter DELETE HISTORY at an arrow prompt
(=>) to remove all previous answers sets and begin at L1.  Use the
SAVE command to store any important profiles or answer sets before
using DELETE HISTORY.

=> s L3 and vector
  47 FILES SEARCHED...
L4          44 L3 AND VECTOR

=> s L4 and express
=> s l4 and express?
  24 FILES SEARCHED...
  25 FILES SEARCHED...
  46 FILES SEARCHED...
  63 FILES SEARCHED...
L5          44 L4 AND EXPRESS?

=> d L5

L5    ANSWER 1 OF 44  BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
AN    1997-03702  BIOTECHDS
TI    New Factor-VIII:c analogs;
         protein engineering with a Factor-V A- and/or C-domain, for increased
         half-life and/or specific activity; use in hemophilia-A therapy and
         gene therapy
AU    Hung D T
PA    Chiron
LO    Emeryville, CA, USA.
PI    WO 9703191 30 Jan 1997
AI    WO 1996-US11013 28 Jun 1996
PRAI  US 1995-1030 11 Jul 1995
DT    Patent
LA    English
OS    WPI: 1997-119047 [11]


=> d L5 2-44 ibib,abs

L5   ANSWER 2 OF 44  IFIPAT  COPYRIGHT 2005 IFI on STN
AN                        10376644  IFIPAT;IFIUDB;IFICDB
TITLE:                    COMPOSITIONS AND METHODS OF USE OF MAMMALIAN
                          RETROTRANSPOSONS
INVENTOR(S):              DeBerardinis; Ralph, Philadelphia, PA, US
                          Kazazian; Haig H. JR., Baltimore, MD, US
                          Ostertag; Eric, Philadelphia, PA, US
PATENT ASSIGNEE(S):       The Trustees Of The University Of Pennsylvania, US
AGENT:                    MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,
                          PHILADELPHIA, PA, 19103-2921, US

                             NUMBER          PK    DATE
                          -----------------  --  --------
PATENT INFORMATION:       US 2003121063      A1  20030626
APPLICATION INFORMATION:  US 2002-216122          20020809

                                                      GRANTED PATENT NO.
                          APPLN. NUMBER             DATE    OR STATUS
                          -----------------       --------  ------------------
CONTINUATION-IN-PART OF:  US 1996-749805          19961115
```

CONTINUATION-IN-PART OF:	US 2000-653812	20000901	
DIVISION OF:	US 1997-847844	19970428	6150160

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 1995-6831P	19951116 (Provisional)
FAMILY INFORMATION:	US 2003121063	20030626
	US 6150160	
DOCUMENT TYPE:	Utility	
	Patent Application - First Publication	
FILE SEGMENT:	CHEMICAL	
	APPLICATION	
OTHER SOURCE:	CA 139:48143	

GOVERNMENT INTEREST:

(0002) This invention was supported in part by funds from the U. S. Government (NIH Grant Nos. GM45398, GM36481 and CA16519) and the U.S. Government may therefore have certain rights in the invention.

PARENT CASE DATA:

This application is a continuation-in-part application of copending U.S. patent application Ser. No. 09/653,812, filed Sep. 1, 2000, which is a divisional of U.S. application Ser. No. 08/ 847,844, filed Apr. 28, 1997, now U.S. Pat. No. 6,150,160, which is a continuation-in-part of U.S. patent application Ser. No. 08/749,805, filed on Nov. 15, 1996, now abandoned, which claims priority under 35 U.S.C. section 119(e) to U.S. Provisional Patent Application No. 60/006,831, filed on Nov. 16, 1995.

NUMBER OF CLAIMS: 22 26 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1 comprises FIGS. 1A through 1B. FIG. 1A is a diagram depicting the organization of a 6.0 kb human L1 element. ORF1 and ORF2 are indicated by dark rectangles; the 5' and 3' untranslated regions are indicated by shaded rectangles and the untranslated region between ORF1 and ORF2 is indicated by a white stripe. The approximate position of the endonuclease (EN), reverse transcriptase (RT), cysteine-rich C. motif and poly A tail (AAAAA)n are indicated. Arrows indicate the target site duplications which flank the element. FIG. 1B is a diagram of an overview of a retrotransposition assay. The element L1.2 was tagged with an indicator gene (mneoI) containing an antisense copy of the neo gene disrupted by intron 2 of the gamma-globin gene in the sense orientation. The splice donor (SD) and splice acceptor (SA) sites of the intron are indicated on the figure. The neo gene is also flanked by a heterologous promoter (P') and a polyadenylation signal (A') denoted by the striped triangles. Transcripts originating from the promoter driving L1. 2mneoI ***expression*** (P) can splice the intron, but continue to contain an antisense copy of the neo gene. G418-resistant (G418R) colonies should arise only when this transcript is reverse transcribed, integrated into chromosomal DNA, and **expressed** from its own promoter, P'.

FIG. 2A is a diagram depicting cloning of L1.2mneoI. L1.2mneoI was cloned into pCEP4 to create pJM101. pCEP4 contains an origin of replication (Ori) and a selectable marker (Amp) for prokaryotic cells and an origin of replication and transacting factor (Ori/EBNA1) and a selectable marker (Hyg) for eukaryotic cells. The direction of transcription of each gene is denoted by arrows. The features of L1.2mneoI are described in the description of FIG. 1.

FIG. 2B, comprising FIGS. 2Bi through 2Biii, is a diagram depicting mutant constructs of L1.2mneoI. FIG. 2Bi depicts the construct pJM102, which lacks the 910 bp 5' UTR of L1.2; FIG. 2Bii depicts the construct pJM103, which has a 3.8 kb deletion wherein most of the 5' UTR, all of ORF1 and the first 2.1 kb of ORF2 are deleted; FIG. 2Biii depicts the construct pJM105, which contains a missense mutation (D702Y) in ORF2. Each of the mutants have the pCEP4 sequences as the **vector** portion.

FIG. 3A is a diagram outlining the L1.2mneoI retrotransposon assay. HeLa cells were transfected with the desired constructs using lipofectamine.

transgenic mice. Insertion #1 is 1.9 kb in length and contains an inversion of the 5' end with a 73 bp deletion at the inversion point. A 63-bp poly A tail is added after the SV40 poly A signal, and the insertion is flanked by 14 bp target site duplications (TSD), in uppercase letters. The flanking sequence is in lower case. FIG. 23B depicts an L1 insertion in a transgenic mouse. Insertion #2 is 4.3 kb in length. It contains a 92 bp poly A tail added after the SV40 poly A signal, and the insertion is flanked by 6-bp target site duplications. The L1 inserted into intron 1 of a predicted gene (mCG57584 Celera Discovery System) on chromosome 9.!

L5 ANSWER 3 OF 44 IFIPAT COPYRIGHT 2005 IFI on STN

AN	03506846 IFIPAT;IFIUDB;IFICDB
TITLE:	PROTEIN COMPLEXES HAVING **FACTOR VIII**:C ACTIVITY AND PRODUCTION THEREOF; NUCLEOTIDE SEQUENCES CODING ANTIHEMOPHILIC FACTOR; FOR THE TREATMENT OF HEMOPHILA
INVENTOR(S):	Burke; Rae Lyn, San Francisco, CA Chapman; Barbara, Berkeley, CA Mikkelson; Jan Moller, Gentofte, DK Rasmussen; Mirella Ezban, Copenhagen, DK
PATENT ASSIGNEE(S):	Chiron Corporation, Emeryville, CA Novo Nordisk A/S, Bagsvaerd, DK
PRIMARY EXAMINER:	Low, Christopher S. F
ASSISTANT EXAMINER:	Bugaisky, Gabriele E
AGENT:	Blackburn, Robert P. Guth, Joseph H. Robins, Roberta L.

	NUMBER	PK	DATE
PATENT INFORMATION:	US 6228620	B1	20010508
APPLICATION INFORMATION:	US 1995-441943		19950516
EXPIRATION DATE:	8 May 2018		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 1991-652099	19910207	ABANDONED
CONTINUATION-IN-PART OF:	US 1986-822989	19860127	ABANDONED
CONTINUATION-IN-PART OF:	US 1987-51916	19870519	ABANDONED
DIVISION OF:	US 1993-161770	19931203	5595886
FAMILY INFORMATION:	US 6228620	20010508	
	US 5595886		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	CHEMICAL GRANTED		

NUMBER OF CLAIMS: 91

AB Recombinant protein complexes having human **Factor VIII**:C activity are **expressed** in a eukaryotic host cell by transforming the host cell with first and second **expression** cassettes encoding a first polypeptide substantially homologous to human **Factor VIII**:C A **domain** and a second polypeptide substantially homologous to human **Factor VIII**:C C **domain**, respectively. In the present invention, the first polypeptide may be extended having at its Cterminal a human **Factor VIII**:C B **domain** N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human **Factor VIII**:C B **domain** C-terminal peptide. **Expression** of the second polypeptide is improved by employing an alpha1 -antitrypsin signal sequence.

CLMN 91

L5 ANSWER 4 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2005:105707 USPATFULL
TITLE: Gene delivery to tumors
INVENTOR(S): Sullivan, Sean M., Gainesville, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005090646	A1	20050428
APPLICATION INFO.:	US 2004-864774	A1	20040609 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-476941P	20030609 (60)
	US 2004-557030P	20040326 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AKERMAN SENTERFITT, P.O. BOX 3188, WEST PALM BEACH, FL, 33402-3188, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 3310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions for gene therapy for tumors. Cytotoxic agents are selectively **expressed** in endothelial cells of tumor blood vessels, and delivered to tumor cells adjacent to the blood vessels, producing a bystander effect such that all the cells in contact with the transfected cells are killed or permanently growth arrested. In particular, cytotoxic gene products secreted from the transfected cell using a secretory signal sequence, include a membrane permeability domain at the N- or C-terminus that can shuttle the cytotoxic domain into non-transfected cells and back into transfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2005:105498 USPATFULL
TITLE: Human tumor necrosis factor receptors TR21 and TR22
INVENTOR(S): Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005090436	A1	20050428
APPLICATION INFO.:	US 2003-620562	A1	20030717 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-910562, filed on 23 Jul 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US23124	20010723
	US 2000-220116P	20000724 (60)
	US 2000-221143P	20000727 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)

LINE COUNT: 9000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to two novel proteins, TR21 and TR22, which are members of the tumor necrosis factor (TNF) receptor. In particular, isolated nucleic acid molecules are provided encoding the human TR21 and TR22 protein. TR21 and TR22 polypeptides are also provided as are **vectors**, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 and TR22 activity; and methods of treating immune disorders by administering TR21 and TR22 polynucleotides, polypeptides, agonists, and antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2005:104996 USPATFULL
TITLE: Novel proteins with targeted binding
INVENTOR(S): Kolkman, Joost, Voetweg 13, BELGIUM
Stemmer, Willem P.C., Los Gatos, CA, UNITED STATES
Freskgard, Per-Ola, Norrkoping, SWEDEN
PATENT ASSIGNEE(S): Avidia Research Institute, Mountain View, CA, UNITED STATES (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005089932	A1	20050428
APPLICATION INFO.:	US 2004-871602	A1	20040617 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-840723, filed on 5 May 2004, PENDING Continuation-in-part of Ser. No. US 2003-693056, filed on 24 Oct 2003, PENDING Continuation-in-part of Ser. No. US 2003-693057, filed on 24 Oct 2003, PENDING Continuation-in-part of Ser. No. US 2002-289660, filed on 6 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-133128, filed on 26 Apr 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-374107P	20020418 (60)
	US 2001-333359P	20011126 (60)
	US 2001-337209P	20011119 (60)
	US 2001-286823P	20010426 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 97
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Page(s)
LINE COUNT: 6019
AB Methods for identifying discrete monomer domains and immuno-domains with a desired property are provided. Methods for generating multimers from two or more selected discrete monomer domains are also provided, along with methods for identifying multimers possessing a desired property. Presentation systems are also provided which present the discrete monomer and/or immuno-domains, selected monomer and/or immuno-domains, multimers and/or selected multimers to allow their selection. Compositions, libraries and cells that **express** one or more library member, along with kits and integrated systems, are also included in the present invention.

L5 ANSWER 7 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2005:87833 USPATFULL

TITLE: Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa

INVENTOR(S): Chen, Wei, San Diego, CA, UNITED STATES
Fu, Xiaoli, Carlsbad, CA, UNITED STATES
Nouraini, Sherry, Vista, CA, UNITED STATES
Zhang, Zhiqing, Carlsbad, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005075298	A1	20050407
APPLICATION INFO.:	US 2003-353149	A1	20030127 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-280769, filed on 25 Oct 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-401465P	20020805 (60)
	US 2002-353885P	20020131 (60)
	US 2002-353923P	20020131 (60)
	US 2002-353964P	20020131 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ATTN: Louis C Cullman, Stradling Yocca Carlson & Rauth, Suite 1600, 660 Newport Center Drive, Newport Beach, CA, 92660
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions are provided for in vivo heterologous nucleic acid delivery using genetically modified microflora. Specifically, compositions and related methods for the delivery of heterologous nucleic acids to the intestinal mucosa of animals are provided. Specifically, genetically modified microflora are used to deliver transforming heterologous nucleic acids directly, or genetically modified microflora **expressing** at least one heterologous nucleic acid are provided. Representative microflora include bacteria, bacterial fusions, and yeast. The heterologous nucleic acid may encode for immunoprotective epitopes (antigens) or other gene therapy applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2005:37507 USPATFULL
TITLE: Regulatory zinc finger proteins
INVENTOR(S): Kim, Jin-Soo, Daejeon, KOREA, REPUBLIC OF
Shin, Hyun-Chul, Daejon, KOREA, REPUBLIC OF
Kwon, Heung-Sun, Daejon, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005032186	A1	20050210
APPLICATION INFO.:	US 2003-732620	A1	20031209 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-431892P	20021209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 36

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 5012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are chimeric zinc finger proteins that can regulate endogenous genes. Examples of such proteins include proteins that can regulate VEGF-A **expression**. The proteins and nucleic acid encoding them can be used to modulate angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:334808 USPATFULL
TITLE: Novel human leucine-rich repeat containing protein **expressed** predominately in small intestine, HLRRSI1
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004265890	A1	20041230
APPLICATION INFO.:	US 2004-882761	A1	20040701 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-257774P	20001222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 14389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are **vectors**, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:299230 USPATFULL
TITLE: Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
INVENTOR(S): Zhang, Jianzhong, North Wales, PA, UNITED STATES
Cress, Dean Ervin, Souderton, PA, UNITED STATES
Palli, Subba Reddy, Lansdale, PA, UNITED STATES
Dhadialla, Tarlochart Singh, Chalfont, PA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2004235097 A1 20041125
APPLICATION INFO.: US 2004-490976 A1 20040325 (10)
WO 2002-US5234 20020220

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60325534	20010926

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Camille Jolly Tornetta, RheoGene, 2650 Eisenhower Avenue, Norristown, PA, 19403
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 3812
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to **vectors** comprising them and to their uses, in particular in methods for modulating gene **expression** in an ecdysone receptor-based gene **expression** modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:294587 USPATFULL
TITLE: Compositions and methods for increasing packaging and yield of recombinant adenoviruses using multiple packaging signals
INVENTOR(S): Gao, Guangping, Rosemont, PA, United States
Wilson, James M., Gladwyne, PA, United States
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6821512	B1	20041123	
	WO 2001040455		20010607	
APPLICATION INFO.:	US 2002-169544		20020530	(10)
	WO 2000-US32235		20001127	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169025P	19991203 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Guzo, David
LEGAL REPRESENTATIVE: Howson and Howson
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A recombinant adenoviral **vector** which has multiple adenovirus packaging domains is provided. This **vector** has advantages over conventional adenoviral **vectors** in packaging plasmid **vectors** into adenoviral capsids. Methods of making and using this **vector** are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:273303 USPATFULL
TITLE: Antibodies against PD-1 and uses therefor
INVENTOR(S): Collins, Mary, Natick, MA, UNITED STATES
Wood, Clive R., Boston, MA, UNITED STATES
Carreno, Beatriz M., Acton, MA, UNITED STATES
Luxenberg, Deborah, Melrose, MA, UNITED STATES
Jussif, Jason, Salem, NH, UNITED STATES
Carter, Laura L., Medford, MA, UNITED STATES
Bennett, Frances K., Sudbury, MA, UNITED STATES
Valge-Archer, Viia, Little Abington, UNITED KINGDOM
Andrews, John, Little Hadham Ware, UNITED KINGDOM
Russell, Caroline, Royston, UNITED KINGDOM
PATENT ASSIGNEE(S): Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)
Cambridge Antibody Technology, Cambridge, UNITED KINGDOM (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004213795	A1	20041028	
APPLICATION INFO.:	US 2003-741481	A1	20031222	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-435354P	20021223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Mary K. Ferguson, FINNEGAN, HENDERSON, FARABOW,, GARRETT & DUNNER, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 2114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:267736 USPATFULL
TITLE: Differentiation proteins
INVENTOR(S): Lee, Dong-Ki, Daejeon, KOREA, REPUBLIC OF
Lee, Yangsoon, Daejeon, KOREA, REPUBLIC OF
Kim, Jin-Soo, Daejeon, KOREA, REPUBLIC OF
PATENT ASSIGNEE(S): TOOLGEN, INC (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004209277	A1	20041021	
APPLICATION INFO.:	US 2003-669861	A1	20030924	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-314669, filed on 9 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-338441P	20011207 (60)
	US 2002-376053P	20020426 (60)

	US 2002-400904P	20020802 (60)	
	US 2002-401089P	20020805 (60)	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 8164
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The disclosure describes artificial chimeric transcription factors that include at least one zinc finger domains and that can regulate cellular differentiation, for example, a neuronal cell phenotype or an osteoblast phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:254335 USPATFULL
TITLE: Leafthopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
INVENTOR(S): Palli, Subba Reddy, Lansdale, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004197861	A1	20041007	
APPLICATION INFO.:	US 2004-490971	A1	20040325	(10)
	WO 2002-US5026		20020220	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60325096	20010926

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Camille Jolly-Tornetta, RheoGene, 2650 Eisenhower Avenue, Norristown, PA, 19403
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 3776
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invetion relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also realtes to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to **vectors** comprising them and to their uses, in particular in methods for modulating gene eypression in an ecdysone receptor-based gene **expression** modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:232975 USPATFULL
TITLE: Bispecific molecules and uses thereof
INVENTOR(S): Himawan, Jeff, Tampa, FL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004180046	A1	20040916	
APPLICATION INFO.:	US 2004-258650	A1	20040303	(10)
	WO 2001-US13161		20010424	

	NUMBER	DATE

PRIORITY INFORMATION:	US 2000-199903P	20000426 (60)
	US 2000-244812P	20001101 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 119
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2677
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to bispecific molecules that are characterized by having a first binding domain which binds an antigen present in the circulation of a mammal and a second binding domain which binds the C3b-like receptor (known as complement receptor 1 (CR1) or CD35 in primates). The bispecific molecules do not consist of a first monoclonal antibody to CR1 that has been chemically cross-linked to a second monoclonal antibody. The invention also relates to methods of making the bispecific molecules and therapeutic uses thereof, as well as to kits containing the bispecific molecules. The invention further provides polyclonal populations of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal populations of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:221879 USPATFULL
TITLE: Oxadiazoline ligands for modulating the **expression** of exogenous genes via an ecdysone receptor complex
INVENTOR(S): Hormann, Robert Eugene, Melrose Park, PA, UNITED STATES
Chortyk, Orestes, Thompson Station, TN, UNITED STATES
Le, Dat Phat, North Wales, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004171651	A1	20040902	
APPLICATION INFO.:	US 2004-783810	A1	20040219	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-449467P	20030221 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Rheo Gene INC., 2650 Eisenhower Avenue, Norristown, PA, 19403
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 6195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene **expression** system, and a method to modulate exogenous gene **expression** in which an ecdysone receptor complex comprising: a DNA binding **domain**; **a** ligand binding **domain**; **a** transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:158597 USPATFULL

TITLE: Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses

INVENTOR(S): Fraser, Christopher C., Lexington, MA, UNITED STATES
Barnes, Thomas M., Brookline, MA, UNITED STATES
Sharp, John D., Arlington, MA, UNITED STATES
Kirst, Susan J., Brookline, MA, UNITED STATES
Myers, Paul S., Cambridge, MA, UNITED STATES
Leiby, Kevin R., Natick, MA, UNITED STATES
Holtzman, Douglas A., Jamaica Plain, MA, UNITED STATES
McCarthy, Sean A., San Diego, CA, UNITED STATES
Wrighton, Nicholas, Winchester, MA, UNITED STATES
MacKay, Charles R., Vaucluse, AUSTRALIA
Goodearl, Andrew D.J., Natick, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004121396	A1	20040624
APPLICATION INFO.:	US 2003-741790	A1	20031219 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-759130, filed on 12 Jan 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-479249, filed on 7 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-559497, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-578063, filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-333159, filed on 14 Jun 1999, PENDING Continuation-in-part of Ser. No. US 2000-596194, filed on 16 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-342364, filed on 29 Jun 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-608452, filed on 30 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-393996, filed on 10 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-602871, filed on 23 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-420707, filed on 19 Oct 1999, ABANDONED

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139

NUMBER OF CLAIMS: 85

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 365 Drawing Page(s)

LINE COUNT: 12420

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, **expression vectors** containing the nucleic acid molecules of the invention, host cells into which the **expression vectors** have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:133830 USPATFULL
TITLE: Gene **expression** system based on chimeric receptors
INVENTOR(S): Gage, Fred H, La Jolla, CA, UNITED STATES
Suhr, Steven T, La Jolla, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004102367	A1	20040527	
APPLICATION INFO.:	US 2002-181325	A1	20021122	(10)
	WO 2001-US5750		20010223	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1953
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a system for modulating the **expression** of a target gene in a subject wherein a defined response element for a DNA binding domain modulates **expression** of said target gene. The invention system comprises two chimeric proteins, each containing the dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily, one of which is non-endogenous to the subject. In addition, the first chimeric protein contains a DNA binding domain to which the target gene is responsive and the second chimeric protein contains a transcription modulating domain, such as a transcription activator or a transcription repressor. In one embodiment of the invention, two invention systems form a dimer having the properties of a native heterodimer or homodimer. In another embodiment, only the first chimeric protein contains a DNA binding domain and only the second chimeric protein contains a transcription activating domain. The functional entity formed by association of the first and second chimeric proteins can be designed to transactivate transcription by complexing with a DNA binding recognition site that does not have the 2-half site format common to response elements for members of the steroid/thyroid hormone nuclear receptor superfamily. Thus, certain of the invention systems cannot functionally interact with endogenous proteins in the way that wild type receptors do. The invention further provides nucleic acid sequences encoding the invention chimeric proteins, cells containing such nucleic acid sequences, and methods for using the invention chimeric proteins to modulate **expression** of one or more non-endogenous genes in a subject organism.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:126963 USPATFULL
TITLE: Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene **expression** system
INVENTOR(S): Kapitskaya, Marianna Zinovjevna, North Wales, PA, UNITED STATES
Palli, Subba Reddy, Lansdale, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004096942	A1	20040520

APPLICATION INFO.: US 2003-468199 A1 20031217 (10)
WO 2002-US5706 20020220
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Rachel Rondinelli, Rohm & Haas Company, 100 Independence Mall West, Philadelphia, PA, 19106-2399
NUMBER OF CLAIMS: 65
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene **expression**. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene **expression** system and methods of modulating gene **expression** in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation traits in transgenic organisms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:64518 USPATFULL
TITLE: Ketone ligands for modulating the **expression** of exogenous genes via an ecdysone receptor complex
INVENTOR(S): Tice, Colin M., Elkins Park, PA, UNITED STATES
Michelotti, Enrique L., Fort Washington, PA, UNITED STATES
Hormann, Robert E., Melrose Park, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049037	A1	20040311
APPLICATION INFO.:	US 2003-614116	A1	20030703 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-393960P	20020705 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: RheoGene, Inc., 2650 Eisenhower Avenue, Norristown, PA, 19403
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 8313
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a method to modulate exogenous gene **expression** in which an ecdysone receptor complex comprising: a DNA binding **domain**; **a** ligand binding **domain** ; **a** transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:44607 USPATFULL
TITLE: Ecdysone receptor-based inducible gene

expression system

INVENTOR(S): Palli, Subba Reddy, Lansdale, PA, UNITED STATES
Kapitskaya, Marianna Zinovjevna, North Wales, PA, UNITED STATES
Cress, Dean Ervin, Sounderton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033600	A1	20040219
APPLICATION INFO.:	US 2002-239134	A1	20020919 (10)
	WO 2001-US9050		20010321

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NEW RHEOGENE I LLC, 2650 EISENHOWER AVENUE, NORRISTOWN, PA, 19403
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 5380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene **expression** More specifically, this invention relates to a novel inducible gene **expression** system and methods of modulating gene **expression** in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2004:24751 USPATFULL
TITLE: Combinatorial DNA library for producing modified N-glycans in lower eukaryotes

INVENTOR(S): Gerngross, Tillman U., Hanover, NH, UNITED STATES
Wildt, Stefan, Lebanon, NH, UNITED STATES
Choi, Byung-Kwon, Norwich, VT, UNITED STATES
Nett, Juergen Hermann, Grantham, NH, UNITED STATES
Bobrowicz, Piotr, White River Junction, VT, UNITED STATES
Hamilton, Stephen R., Enfield, NH, UNITED STATES
Davidson, Robert C., Enfield, NH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018590	A1	20040129
APPLICATION INFO.:	US 2003-371877	A1	20030220 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-892591, filed on 27 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214358P	20000628 (60)
	US 2000-215638P	20000630 (60)
	US 2001-279997P	20010330 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 45 Drawing Page(s)
LINE COUNT: 5213

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous **expression** of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and **express** mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to **express** and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man.sub.5GlcNAc.sub.2 core structure which may then be modified further by heterologous **expression** of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:13415 USPATFULL

TITLE: Methods and composition for delivering nucleic acids and/or proteins to the respiratory system

INVENTOR(S): Chen, Wei, San Diego, CA, UNITED STATES
Fu, Xiaoli, Carlsbad, CA, UNITED STATES
Nouraini, Sherry, Vista, CA, UNITED STATES
Zhang, Zhiqing, Carlsbad, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009937	A1	20040115
APPLICATION INFO.:	US 2003-353137	A1	20030127 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-280769, filed on 25 Oct 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-401465P	20020805 (60)
	US 2002-353885P	20020131 (60)
	US 2002-353923P	20020131 (60)
	US 2002-353964P	20020131 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OPPENHEIMER WOLFF & DONNELLY LLP, 840 NEWPORT CENTER DRIVE, SUITE 700, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compostions related to the fields of bacteriology, immunology and gene therapy are provided. In general modified microflora for the delivery of vaccines, allergens and therapeutics to the mucosal surfaces of the respiratory tract are provided. In particular, the compositions and methods are directed at inducing an M-cell mediated immune response to pathogenic diseases. Specifically, methods of vaccine preparation, delivery and mucosal immunization using a Lactic Acid Bacteria (LAB), yeast and LAB that have been modified through fusion with E. coli to either present on its cell surface, or secrete, antigenic epitopes derived from pathogenic microorganisms and/or to secrete a therapeutic protein sequence are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2003:335013 USPATFULL
TITLE: Materials and methods involving conditional retention domains
INVENTOR(S): Rivera, Victor, Arlington, MA, UNITED STATES
Clackson, Timothy P., Arlington, MA, UNITED STATES
Rothman, James E., New York, NY, UNITED STATES
PATENT ASSIGNEE(S): ARIAD Gene Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235889	A1	20031225
APPLICATION INFO.:	US 2003-440799	A1	20030519 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-420819, filed on 19 Oct 1999, GRANTED, Pat. No. US 6566073 Continuation of Ser. No. US 1998-174799, filed on 19 Oct 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-104743P	19981019 (60)
	US 1999-137787P	19990602 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ARIAD Gene Therapeutics, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 3859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials and methods involving conditional retention domains (CRDs) are disclosed. Also disclosed are fusion proteins containing CRDs and cells **expressing** such fusion proteins. In addition, the invention provides novel methods for producing target proteins in vivo using fusion proteins containing conditional retention domains and methods for identifying novel CRDs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2003:276702 USPATFULL
TITLE: Phenotypic screen of chimeric proteins
INVENTOR(S): Kim, Jin-Soo, Yuseong-gu, KOREA, REPUBLIC OF
Park, Kyung-Soon, Yuseong-gu, KOREA, REPUBLIC OF
Lee, Dong-Ki, Yuseong-gu, KOREA, REPUBLIC OF
Seol, Wongi, Yuseong-gu, KOREA, REPUBLIC OF
Lee, Horim, Chungcheongnam-do, KOREA, REPUBLIC OF
Lee, Seong-Il, Yuseong-gu, KOREA, REPUBLIC OF
Yang, Hyo-Young, Yuseong-gu, KOREA, REPUBLIC OF
Lee, Yangsoon, Yuseong-gu, KOREA, REPUBLIC OF
Jang, Young-Soon, Yuseong-gu, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003194727	A1	20031016
APPLICATION INFO.:	US 2002-314669	A1	20021209 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-338441P	20011207 (60)

	US 2002-376053P 20020426 (60)
	US 2002-400904P 20020802 (60)
	US 2002-401089P 20020805 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS:	111
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	28 Drawing Page(s)
LINE COUNT:	5577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 44 USPATFULL on STN

ACCESSION NUMBER:	~~2003~~:238378 USPATFULL
TITLE:	Modified **factor VIII**
INVENTOR(S):	Lollar, John S., Decatur, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166536	A1	20030904
APPLICATION INFO.:	US 2002-131510	A1	20020423 (10)

RELATED APPLN. INFO.:	Division of Ser. No. US 1999-315179, filed on 20 May 1999, GRANTED, Pat. No. US 6376463 Continuation-in-part of Ser. No. US 1998-37601, filed on 10 Mar 1998, GRANTED, Pat. No. US 6180371 Continuation-in-part of Ser. No. US 1996-670707, filed on 26 Jun 1996, GRANTED, Pat. No. US 5859204 Continuation-in-part of Ser. No. WO 1994-US13200, filed on 15 Nov 1994, PENDING Continuation-in-part of Ser. No. US 1994-212133, filed on 11 Mar 1994, GRANTED, Pat. No. US 5663060 Continuation-in-part of Ser. No. US 1992-864004, filed on 7 Apr 1992, GRANTED, Pat. No. US 5364771 Continuation-in-part of Ser. No. WO 1997-US11155, filed on 26 Jun 1997, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	GREENLEE WINNER AND SULLIVAN P C, 5370 MANHATTAN CIRCLE, SUITE 201, BOULDER, CO, 80303
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Page(s)
LINE COUNT:	5600

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Specific amino acid loci of human **factor VIII** interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with **factor VIII**. Modified **factor VIII** is disclosed in which the amino acid sequence is changed by a substitution at one or more amino acids of positions 484-508 of the A2 domain. The modified **factor VIII** is useful as a clotting factor supplement for hemophiliacs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2003:225297 USPATFULL
TITLE: Glycoprotein compositions
INVENTOR(S): Presta, Leonard G., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157108	A1	20030821
APPLICATION INFO.:	US 2002-277370	A1	20021022 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-337642P	20011025 (60)
	US 2002-347694P	20020109 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 4803
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2003:207348 USPATFULL
TITLE: Novel human leucine-rich repeat containing protein **expressed** predominately in bone marrow, HLRRBM1
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143706	A1	20030731
APPLICATION INFO.:	US 2001-28374	A1	20011220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-257773P	20001222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 13850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are **vectors**, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various

diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 44 USPATFULL on STN

ACCESSION NUMBER:	2003:194977 USPATFULL
TITLE:	Human tumor necrosis factor receptor TR16
INVENTOR(S):	Baker, Kevin P., Darnestown, MD, UNITED STATES Young, Paul E., Gaithersburg, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003134788	A1	20030717	
APPLICATION INFO.:	US 2002-73333	A1	20020213	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-637856, filed on 10 Aug 2000, ABANDONED			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-268364P	20010214	(60)
	US 1999-148348P	19990812	(60)
	US 1999-148683P	19990813	(60)
	US 1999-148758P	19990816	(60)
	US 1999-148870P	19990813	(60)
	US 1999-149181P	19990817	(60)
	US 1999-149453P	19990818	(60)
	US 1999-149498P	19990819	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	20 Drawing Page(s)
LINE COUNT:	13800

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel protein, TR16, which is a member of the tumor necrosis factor (TNF) receptor superfamily and the TRAIL receptor subfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR16 protein. TR16 polypeptides are also provided as are **vectors**, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR16 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 44 USPATFULL on STN

ACCESSION NUMBER:	2003:175214 USPATFULL
TITLE:	Compositions and methods of use of mammalian retrotransposons
INVENTOR(S):	Kazazian, Haig H., JR., Baltimore, MD, UNITED STATES Ostertag, Eric, Philadelphia, PA, UNITED STATES DeBerardinis, Ralph, Philadelphia, PA, UNITED STATES
PATENT ASSIGNEE(S):	The Trustees Of The University Of Pennsylvania (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003121063	A1	20030626	
APPLICATION INFO.:	US 2002-216122	A1	20020809	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-653812, filed on 1 Sep 2000, PENDING Division of Ser. No. US 1997-847844, filed on 28 Apr 1997, GRANTED, Pat. No. US 6150160 Continuation-in-part of Ser. No. US 1996-749805, filed on 15 Nov 1996, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-6831P	19951116 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Page(s)
LINE COUNT: 4178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to an isolated DNAc molecule comprising a promoter P and an L1 cassette sequence comprising a core L1 retrotransposon element and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2003:136920 USPATFULL
TITLE: Materials and methods involving conditional retention domains
INVENTOR(S): Rivera, Victor, Arlington, MA, United States
Clackson, Timothy, Cambridge, MA, United States
Rothman, James, New York, NY, United States
PATENT ASSIGNEE(S): Ariad Gene Therapeutics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6566073	B1	20030520
APPLICATION INFO.:	US 1999-420819		19991019 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-174799, filed on 19 Oct 1998, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-137787P	19990602 (60)
	US 1998-104743P	19981019 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Horlick, Kenneth R.
ASSISTANT EXAMINER: Wilder, Cynthia
LEGAL REPRESENTATIVE: Berstein, David L.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 3873
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials and methods involving conditional retention domains (CRDs) are disclosed. Also disclosed are fusion proteins containing CRDs and cells **expressing** such fusion proteins. In addition, the invention provides novel methods for producing target proteins in vivo using fusion proteins containing conditional retention domains and methods for identifying novel CRDs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2003:106253 USPATFULL
TITLE: Prokaryotically produced antibodies and uses thereof
INVENTOR(S): Simmons, Laura C., Burlingame, CA, UNITED STATES
Klimowski, Laura, Salt Lake City, UT, UNITED STATES
Reilly, Dorothea, San Francisco, CA, UNITED STATES
Yansura, Daniel G., Pacifica, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073164	A1	20030417
APPLICATION INFO.:	US 2001-20786	A1	20011213 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256164P	20001214 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 3112
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods and compositions for improved **expression** and production of recombinant antibodies in prokaryotic **expression** systems. Particularly contemplated are prokaryotic **expression** and production of full length aglycosylated antibodies. The antibody products of the invention can be used in various aspects of biological research, diagnosis and medical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2003:30332 USPATFULL
TITLE: Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
INVENTOR(S): Fraser, Christopher C., Lexington, MA, UNITED STATES
Barnes, Thomas M., Brookline, MA, UNITED STATES
Sharp, John D., Arlington, MA, UNITED STATES
Kirst, Susan J., Brookline, MA, UNITED STATES
Myers, Paul S., Cambridge, MA, UNITED STATES
Leiby, Kevin R., Natick, MA, UNITED STATES
Holtzman, Douglas A., Jamaica Plain, MA, UNITED STATES
McCarthy, Sean A., San Diego, CA, UNITED STATES
Wrighton, Nicholas, Winchester, MA, UNITED STATES
MacKay, Charles R., Vaucluse, AUSTRALIA
Goodearl, Andrew D.J., Natick, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022279	A1	20030130
APPLICATION INFO.:	US 2001-759130	A1	20010112 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-479249, filed on 7 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-559497, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-578063, filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-333159, filed on 14 Jun 1999, PENDING Continuation-in-part of Ser. No. US 2000-596194, filed on 16 Jun 2000, PENDING Continuation-in-part of Ser.

No. US 1999-342364, filed on 29 Jun 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-608452, filed on 30 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-393996, filed on 10 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-602871, filed on 23 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-420707, filed on 19 Oct 1999, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, Millenium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 85
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 361 Drawing Page(s)
LINE COUNT: 12618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, **expression vectors** containing the nucleic acid molecules of the invention, host cells into which the **expression vectors** have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2003:23722 USPATFULL
TITLE: Novel human leucine-rich repeat containing protein **expressed** predominately in small intestine, HLRRSI1
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003017562	A1	20030123	
	US 6858407	B2	20050222	
APPLICATION INFO.:	US 2001-29347	A1	20011220	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-257774P	20001222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 14217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are **vectors**, host cells, antibodies, and recombinant and synthetic

methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2002:322506 USPATFULL
TITLE: Modified **factor VIII**
INVENTOR(S): Lollar, John S., Decatur, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002182670	A1	20021205
	US 6770744	B2	20040803
APPLICATION INFO.:	US 2001-957641	A1	20010919 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-236460P	20000929 (60)
	US 2000-234047P	20000919 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GREENLEE WINNER and SULLIVAN, P.C., Suite 201, 5370 Manhattan Circle, Boulder, CO, 80303
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 2392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Specific amino acid loci of human **factor VIII** interact with inhibitory antibodies of hemophilia patients after being treated with **factor VIII**. Modified **factor VIII** is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified **factor VIII** is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2002:254199 USPATFULL
TITLE: Modified **factor VIII**
INVENTOR(S): Lollar, John S., Decatur, GA, United States
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458563	B1	20021001
APPLICATION INFO.:	US 2000-523656		20000310 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-37601, filed on 10 Mar 1998, now patented, Pat. No. US 6180371 Continuation-in-part of Ser. No. US 1996-670707, filed on 26 Jun 1996, now patented, Pat. No. US 5859204 Continuation-in-part of Ser. No. US 523656 Continuation-in-part of Ser. No. WO 1997-US11155, filed on 26 Jun 1997
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Schnizer, Holly
LEGAL REPRESENTATIVE: Greenlee Winner and Sullivan PC
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 4222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a modified B-domainless form of porcine **factor VIII**, to a DNA encoding the same, and to the use thereof for treatment of hemophilia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2002:221381 USPATFULL
TITLE: Novel ecdysone receptor-based inducible gene **expression** system
INVENTOR(S): Palli, Subba Reddy, Lansdale, PA, UNITED STATES
Kapitskaya, Marianna Zinovjevna, North Wales, PA, UNITED STATES
Cress, Dean Ervin, Souderton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119521	A1	20020829
APPLICATION INFO.:	US 2001-965703	A1	20010926 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US9050, filed on 21 Mar 2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191355P	20000322 (60)
	US 2001-269799P	20010220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROHM AND HAAS COMPANY, PATENT DEPARTMENT, 100 INDEPENDENCE MALL WEST, PHILADELPHIA, PA, 19106-2399
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 6231
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene **expression**. More specifically, this invention relates to a novel inducible gene **expression** system and methods of modulating gene **expression** in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2002:206168 USPATFULL
TITLE: Multiple inducible gene regulation system
INVENTOR(S): Dhadialla, Tarlochan Singh, Indianapolis, IN, UNITED STATES
Cress, Dean Ervin, Souderton, PA, UNITED STATES
Carlson, Glenn Richard, North Wales, PA, UNITED STATES
Hormann, Robert Eugene, Melrose Park, PA, UNITED STATES
Palli, Subba Reddy, Lansdale, PA, UNITED STATES
Kudla, Arthur John, Charlottesville, VA, UNITED STATES

Herzig, Ronald Phillip, JR., Barboursville, VA, UNITED STATES
Philip, Mohan, Charlottesville, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110861	A1	20020815
APPLICATION INFO.:	US 2001-965697	A1	20010927 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237446P	20001003 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz, Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 3413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative **expression** of multiple genes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2002:185256 USPATFULL
TITLE: Human tumor necrosis factor receptors TR21 and TR22
INVENTOR(S): Zeng, Zhi-Zhen, Lansdale, PA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098163	A1	20020725
APPLICATION INFO.:	US 2001-910562	A1	20010723 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US23124	20010723
	US 2000-220116P	20000724 (60)
	US 2000-221143P	20000727 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 9204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to two novel proteins, TR21 and TR22, which are members of the tumor necrosis factor (TNF) receptor. In particular, isolated nucleic acid molecules are provided encoding the human TR21 and TR22 protein. TR21 and TR22 polypeptides are also provided as are **vectors**, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 and TR22

activity; and methods of treating immune disorders by administering TR21 and TR22 polynucleotides, polypeptides, agonists, and antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2002:88455 USPATFULL
TITLE: Modified **factor VIII**
INVENTOR(S): Lollar, John S., Decatur, GA, United States
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376463	B1	20020423
APPLICATION INFO.:	US 1999-315179		19990520 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-670707, filed on 26 Jun 1996, now patented, Pat. No. US 5859204 Continuation-in-part of Ser. No. WO 1994-US13200, filed on 15 Nov 1994 Continuation-in-part of Ser. No. US 1994-212133, filed on 11 Mar 1994 Continuation-in-part of Ser. No. US 1992-864004, filed on 7 Apr 1992, now patented, Pat. No. US 5364771
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: Greenlee Winner and Sullivan, PC
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 5454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Specific amino acid loci of human **factor VIII** interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with **factor VIII**. Modified **factor VIII** is disclosed in which the amino acid sequence is changed by a substitution at one or more amino acids of positions 484-508 of the Az domain. The modified **factor VIII** is useful as a clotting factor supplement for hemophiliacs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 44 USPATFULL on STN
ACCESSION NUMBER: 2002:8587 USPATFULL
TITLE: Multivalent antibodies and uses therefor
INVENTOR(S): Miller, Kathy L., San Francisco, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004587	A1	20020110
APPLICATION INFO.:	US 2001-813341	A1	20010320 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-195819P	20000411 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Attn: Wendy M. Lee, 1 DNA Way, South San Francisco, CA, 94080-4990
NUMBER OF CLAIMS: 93

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 45 Drawing Page(s)
LINE COUNT: 4913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 44 USPATFULL on STN
ACCESSION NUMBER: 92:38505 USPATFULL
TITLE: **Factor VIII** analog, preparation process, and pharmaceutical composition containing it
INVENTOR(S): Meulien, Pierre, Strasbourg, France
Pavirani, Andrea, Strasbourg, France
PATENT ASSIGNEE(S): Transgene S.A., Courbevoie, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5112950		19920512
APPLICATION INFO.:	US 1991-723666		19910626 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1988-228265, filed on 4 Aug 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1987-11415	19870811

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Baker, R. Keith
LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Factor VIII** analog which has undergone deletion of amino acids 771 to 1666, prepared from eukaryotic cells transformed by an **expression vector** carrying the cDNA of the **factor VIII** which has undergone deletion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 43 OF 44 USPAT2 on STN
ACCESSION NUMBER: 2003:23722 USPAT2
TITLE: Human leucine-rich repeat containing protein **expressed** predominately in small intestine, HLRRSI1
INVENTOR(S): Feder, John N., Belle Mead, NJ, United States
Ramanathan, Chandra S., Wallingford, CT, United States
Mintier, Gabriel A., Hightstown, NJ, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6858407	B2	20050222
APPLICATION INFO.:	US 2001-29347		20011220 (10)

	NUMBER	DATE

PRIORITY INFORMATION: US 2000-257774P 20001222 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Nashed, Nashaat T.
LEGAL REPRESENTATIVE: D'Amico, Stephen C.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 14213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are **vectors**, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 44 OF 44 USPAT2 on STN
ACCESSION NUMBER: 2002:322506 USPAT2
TITLE: Modified **factor VIII**
INVENTOR(S): Lollar, John S., Decatur, GA, United States
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6770744	B2	20040803
APPLICATION INFO.:	US 2001-957641		20010919 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-236460P	20000929 (60)
	US 2000-234047P	20000919 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Schnizer, Holly
LEGAL REPRESENTATIVE: Greenlee Winner and Sullivan PC
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2460
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Specific amino acid loci of human **factor VIII** interact with inhibitory antibodies of hemophilia patients after being treated with **factor VIII**. Modified **factor VIII** is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified **factor VIII** is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

61 FILES SEARCHED...
L6 52 NORDFANG

=> d L6 1-52 ibib,abs

L6 ANSWER 1 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2005:40112 USPATFULL
TITLE: Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans
INVENTOR(S): San Antonio, James D., Media, PA, United States
Verrecchio, Angela, Brighton, MA, United States
Schick, Barbara P., Merion Station, PA, United States
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6855801	B1	20050215
APPLICATION INFO.:	US 2000-496391		20000202 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-118276P	19990202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Canella, Karen A.
LEGAL REPRESENTATIVE: Drinker Biddle & Reath LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2040
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention involves peptides of various sequences and sizes and methods of using said peptides with a strong affinity for glycosaminoglycans and proteoglycans, wherein said peptides interact strongly with heparin, other glycosaminoglycans, or proteoglycans (PGs).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:280870 USPATFULL
TITLE: 1-Aroyl-piperidinyl benzamidines
INVENTOR(S): Pauls, Heinz, Flemington, NJ, UNITED STATES
Gong, Yong, Bridgewater, NJ, UNITED STATES
Levell, Julian, Summit, NJ, UNITED STATES
Astles, Peter, Kent, UNITED KINGDOM
Eastwood, Paul R., Essex, UNITED KINGDOM
PATENT ASSIGNEE(S): AVENTIS PHARMACEUTICALS INC, Bridgewater, NJ (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004220171	A1	20041104
APPLICATION INFO.:	US 2003-616141	A1	20030708 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-841417, filed on 24 Apr 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-18306	20000727
	US 2000-200066P	20000427 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE

202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 3209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compounds of formula ##STR1##

which inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:267309 USPATFULL
TITLE: Mini-Ad vector for immunization
INVENTOR(S): Zhang, Wei-Wei, Libertyville, IL, UNITED STATES
Alemany, Ramon, Grayslake, IL, UNITED STATES
Dai, Yifan, Grayslake, IL, UNITED STATES
Josephs, Steven, Grayslake, IL, UNITED STATES
Balague, Cristina, Grayslake, IL, UNITED STATES
Ayares, David, Blacksburgh, VA, UNITED STATES
Schneiderman, Richard, Highland Park, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004208846	A1	20041021
APPLICATION INFO.:	US 2004-837079	A1	20040615 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-658961, filed on 31 May 1996, ABANDONED Continuation-in-part of Ser. No. US 1997-791218, filed on 31 Jan 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-197734P	20000418 (60)
	US 2000-198501P	20000418 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 57 Drawing Page(s)
LINE COUNT: 4461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for treating a disorder such as hemophilia. A method of treating hemophilia in a mammal by administering recombinant virus virions comprising a nucleotide sequence having an adenoviral inverted terminal repeat fusion sequence, a packaging signal, a transcriptional control region, and a nucleic acid encoding a therapeutic protein such as FVIII. In addition, the DNA molecule does not encode an adenoviral protein. It is preferred that the virions be administered to the mammal under conditions that result in the expression of the therapeutic protein at a level that provides a therapeutic effect in said mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:178412 USPATFULL
TITLE: Protein complexes having factor VIII:C activity and production thereof
INVENTOR(S): Chapman, Barbara, Berkeley, CA, UNITED STATES

Burke, Rae Lyn, San Francisco, CA, UNITED STATES
Rasmussen, Mirella Ezban, Copenhagen, DENMARK
Mikkelson, Jan Mollar, Gentofte, DENMARK
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)
Novo Nordisk A/S (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004137579	A1	20040715
APPLICATION INFO.:	US 2003-726199	A1	20031201 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-256849, filed on 26 Sep 2002, ABANDONED Continuation of Ser. No. US 2000-748062, filed on 22 Dec 2000, ABANDONED Continuation of Ser. No. US 1995-441943, filed on 16 May 1995, GRANTED, Pat. No. US 6228620 Division of Ser. No. US 1993-161770, filed on 3 Dec 1993, GRANTED, Pat. No. US 5595886 Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, ABANDONED Continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, ABANDONED Continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Joseph H. Guth, Esq., CHIRON CORPORATION, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 1986
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an α.sub.1-antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:133913 USPATFULL
TITLE: Substituted oxoazaheterocyclyl compounds
INVENTOR(S): Ewing, William R., Yardley, PA, UNITED STATES
Becker, Michael R., Norristown, PA, UNITED STATES
Choi-Sledeski, Yong Mi, Belle Mead, NJ, UNITED STATES
Pauls, Heinz W., Oakville, CANADA
He, Wei, Audobon, PA, UNITED STATES
Condon, Stephen M., Newton, MA, UNITED STATES
Davis, Roderick S., West Chester, PA, UNITED STATES
Hanney, Barbara A., Pennsburg, PA, UNITED STATES
Spada, Alfred P., Carlsbad, CA, UNITED STATES
Burns, Christopher J., Malvern, PA, UNITED STATES
Jiang, John Z., Collegeville, PA, UNITED STATES
Li, Aiwen, Audubon, PA, UNITED STATES
Myers, Michael R., Fishers, IN, UNITED STATES
Lau, Wan F., Groton, CT, UNITED STATES
Poli, Gregory B., Perkasie, PA, UNITED STATES
Bobko, Mark A., Exton, PA, UNITED STATES
Morris, Robert L., Wayne, PA, UNITED STATES

Karpinski, Joseph M., Douglassville, PA, UNITED STATES
Gallagher, Timothy F., Harleysville, PA, UNITED STATES
Neuenschwander, Kent W., Schwenksville, PA, UNITED STATES
Groneberg, Robert D., Boulder, CO, UNITED STATES
Sabuco, Jean-Francois, Paris, FRANCE

PATENT ASSIGNEE(S): AVENTIS PHARMACEUTICALS INC., Bridgewater, NJ, UNITED STATES, 08807-2854 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004102450	A1	20040527
APPLICATION INFO.:	US 2003-628093	A1	20030725 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-363196, filed on 28 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US1682, filed on 27 Jan 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72707P	19980127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
LINE COUNT: 19006
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:114724 USPATFULL
TITLE: N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa

INVENTOR(S): Czekaj, Mark, Doylestown, PA, UNITED STATES
Klein, Scott I., Collegeville, PA, UNITED STATES
Pauls, Heinz W., Oakville, CANADA

PATENT ASSIGNEE(S): AVENTIS PHARMA DEUTSCHLAND GMBH, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004087570	A1	20040506
APPLICATION INFO.:	US 2003-686871	A1	20031016 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-143190, filed on 10 May 2002, ABANDONED Continuation of Ser. No. WO 2000-EP10890, filed on 4 Nov 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-30540	19991223
	US 1999-164621P	19991110 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1
LINE COUNT: 2768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:89011 USPATFULL
TITLE: Piperididinyl and N-amidinopiperidinyl derivatives
INVENTOR(S): Klein, Scott I., Collegeville, PA, UNITED STATES
Guertin, Kevin R., Verona, NJ, UNITED STATES
PATENT ASSIGNEE(S): AVENTIS PHARMACEUTICALS INC., Bridgewater, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004067988	A1	20040408
APPLICATION INFO.:	US 2003-674480	A1	20030930 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-922906, filed on 6 Aug 2001, ABANDONED Division of Ser. No. US 1999-273618, filed on 22 Mar 1999, GRANTED, Pat. No. US 6277865

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79002P	19980323 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 2317
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:24677 USPATFULL
TITLE: Ixodes scapularis tissue factor pathway inhibitor
INVENTOR(S): Francischetti, Ivo M.B., Bethesda, MD, UNITED STATES
Valenzuela, Jesus G., Gaithersburg, MD, UNITED STATES
Ribeiro, Jose M. C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018516	A1	20040129
APPLICATION INFO.:	US 2003-408166	A1	20030404 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2001-US42472, filed on 5

Oct 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240575P	20001005 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 6768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Ixolaris, a novel protein with anticoagulant activity is described. Ixolaris can be isolated from the salivary glands of ticks or made by recombinant methods using various DNA expression techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:272458 USPATFULL
TITLE: Minimal adenoviral vector
INVENTOR(S): Zhang, Wei-Wei, Libertyville, IL, UNITED STATES
Alemany, Ramon, Grayslake, IL, UNITED STATES
Dai, Yifan, Grayslake, IL, UNITED STATES
Josephs, Steven, Grayslake, IL, UNITED STATES
Balague, Cristina, Grayslake, IL, UNITED STATES
Ayares, David, Blacksburgh, VA, UNITED STATES
Schneiderman, Richard, Highland Park, IL, UNITED STATES
PATENT ASSIGNEE(S): GenStar Therapeutics Corp., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003192066	A1	20031009
APPLICATION INFO.:	US 2002-160078	A1	20020528 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-866403, filed on 30 May 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-US10218	19970530

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
NUMBER OF CLAIMS: 112
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 54 Drawing Page(s)
LINE COUNT: 4563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including gene transfer, gene therapy, and gene vaccination. More specifically, this invention is related to the Ad vectors that carry the minimal cis-element of the Ad genome (mini-Ad vector) and are capable of delivering transgenes and/or heterologous DNA up to 36 kb. The generation and propagation of the mini-Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line.

This invention further comprises a methodology for generating a mini-adenoviral (mini-Ad) vector for use in gene therapy of hemophilia and animal test systems for in vivo evaluation of the Ad vectors. More

specifically, this invention describes factor VIII (FVIII) Ad vectors that only contain minimal cis-elements of the Ad genome (so called mini-Ad) and comprise a human FVIII cDNA with other supporting DNA elements up to 36 kb. The FVIII mini-Ad can be generated and preferentially amplified through the assistance of a packaging-attenuated helper Ad and a helper cell line. This invention also reports designs and methods for producing transgenic mouse models that can be used for in vivo testing the mini-Ad.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:244416 USPATFULL
TITLE: Protein complexes having factor VIII:C activity and production thereof
INVENTOR(S): Chapman, Barbara, Berkeley, CA, UNITED STATES
Burke, Rae Lyn, San Francisco, CA, UNITED STATES
Rasmussen, Mirella Ezban, Copenhagen, DENMARK
Mikkelson, Jan Moller, Gentofte, DENMARK
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170825	A1	20030911
APPLICATION INFO.:	US 2002-256849	A1	20020926 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-748062, filed on 22 Dec 2000, ABANDONED Continuation of Ser. No. US 1995-441943, filed on 16 May 1995, GRANTED, Pat. No. US 6228620 Division of Ser. No. US 1993-161770, filed on 3 Dec 1993, GRANTED, Pat. No. US 5595886 Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, ABANDONED Continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, ABANDONED Continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CHIRON CORPORATION, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 1944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an α.sub.1-antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:220313 USPATFULL
TITLE: Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds
INVENTOR(S): Dankulich, William P., Collegeville, PA, UNITED STATES
McGarry, Daniel G., Bedminster, NJ, UNITED STATES
Burns, Christopher, Malvern, PA, UNITED STATES
Gallagher, Timothy F., Harleysville, PA, UNITED STATES

Volz, Francis A., Neshanic Station, NJ, UNITED STATES
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., Bridgewater, NJ (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153604	A1	20030814
APPLICATION INFO.:	US 2003-372499	A1	20030224 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-609103, filed on 30 Jun 2000, GRANTED, Pat. No. US 6541505 Continuation of Ser. No. WO 1999-US30623, filed on 22 Dec 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113710P	19981224 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 7958
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:210031 USPATFULL
TITLE: Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
INVENTOR(S): Choi-Sledeski, Yong Mi, Collegeville, PA, United States
Pauls, Henry W., Collegeville, PA, United States
Barton, Jeffrey N., Philadelphia, PA, United States
Ewing, William R., Downingtown, PA, United States
Green, Daniel M., Ambler, PA, United States
Becker, Michael R., Norristown, PA, United States
Gong, Yong, Norristown, PA, United States
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6602864	B1	20030805
APPLICATION INFO.:	US 1998-90492		19980603 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1997-US22406, filed on 3 Dec 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33159P	19961213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Coleman, Brenda
LEGAL REPRESENTATIVE: Parker, III, Raymond S., Newman, Irving
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:134609 USPATFULL
TITLE: N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
INVENTOR(S): Czekaj, Mark, Doylestown, PA, UNITED STATES
Klein, Scott I, Collegeville, PA, UNITED STATES
Pauls, Heinz W., Flemington, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092698	A1	20030515
APPLICATION INFO.:	US 2002-143190	A1	20020510 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-EP10890, filed on 4 Nov 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-30540	19991223
	US 1999-164621P	19991110 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 2752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:106726 USPATFULL
TITLE: Pharmaceutical composition comprising factor VIIa and anti-TFPI
INVENTOR(S): Kjalke, Marianne, Copenhagen N, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073638	A1	20030417
APPLICATION INFO.:	US 2002-271926	A1	20021016 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2001-DK324, filed on 10 May

2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-778	20000510
	DK 2000-771	20000510
	DK 2000-871	20000606
	US 2000-206194P	20000522 (60)
	US 206212P	(60)
	US 2000-212857P	20000620 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1264
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:89407 USPATFULL
TITLE: Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds
INVENTOR(S): Dankulich, William P., Collegeville, PA, United States
McGarry, Daniel G., Bedminster, NJ, United States
Burns, Christopher, Malvern, PA, United States
Gallagher, Timothy F., Harleysville, PA, United States
Volz, Francis A., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., Bridgewater, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6541505	B1	20030401
APPLICATION INFO.:	US 2000-609103		20000630 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1999-US30623, filed on 22 Dec 1999

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113710P	19981224 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Berch, Mark L.
ASSISTANT EXAMINER: Patel, Sudhaker B.
LEGAL REPRESENTATIVE: Parker, III, Raymond S., Newman, Irving
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 7892
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state

associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 52 USPATFULL on STN

ACCESSION NUMBER:	2002:338043 USPATFULL			
TITLE:	Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans			
INVENTOR(S):	Burns, Christopher J., Malvern, PA, UNITED STATES Dankulich, William P., Collegeville, PA, UNITED STATES McGarry, Daniel G., Bedminster, NJ, UNITED STATES Volz, Francis A., Neshanic Station, NJ, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002193410	A1	20021219	
	US 6599918	B2	20030729	
APPLICATION INFO.:	US 2002-81113	A1	20020222	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-IB1562, filed on 12 Aug 2000, UNKNOWN			
	NUMBER		DATE	
PRIORITY INFORMATION:	GB 1999-24155		19991012	
	US 1999-150767P		19990826	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D-303A, BRIDGEWATER, PA, 08807			
NUMBER OF CLAIMS:	31			
EXEMPLARY CLAIM:	1			
LINE COUNT:	3825			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 52 USPATFULL on STN

ACCESSION NUMBER:	2002:201855 USPATFULL			
TITLE:	Method for measuring antithrombin activity			
INVENTOR(S):	Hoogendoorn, Hugh W., Ancaster, CANADA Duncan, Alexander, Decatur, GA, United States Morris, Michael J., South Bend, IN, United States			
PATENT ASSIGNEE(S):	Affinity Biologicals, Inc., Hamilton, CANADA (non-U.S. corporation) R2 Diagnostics, Inc., South Bend, IN, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6432658	B1	20020813	
APPLICATION INFO.:	US 2000-661142		20000913	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			

PRIMARY EXAMINER: Leary, Louise N.
LEGAL REPRESENTATIVE: Kolisch Hartwell Dickinson McCormack & Heuser
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a one-stage method of measuring antithrombin (AT) activity in a sample. In the method, a diluted sample is mixed with AT-deficient plasma containing intrinsic coagulation enzymes, an AT augmenting compound such as heparin, a phospholipid and an activator of the contact phase of the intrinsic coagulation pathway. Following addition of calcium ions, coagulation time is measured and compared to a reference standard to determine the level of AT activity in the sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:181375 USPATFULL
TITLE: Anticoagulant fusion protein anchored to cell membrane
INVENTOR(S): Riesbeck, Kristian, Malmo, SWEDEN
Dorling, Anthony, London, UNITED KINGDOM
George, Andrew John Timothy, Surrey, UNITED KINGDOM
Lechler, Robert Ian, London, UNITED KINGDOM
PATENT ASSIGNEE(S): Imperial College Innovative Limited, London, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6423316	B1	20020723	
	WO 9842850		19981001	
APPLICATION INFO.:	US 2000-402515		20000202	(9)
	WO 1998-GB850		19980326	
			20000202	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-6327	19970326
	GB 1997-20248	19970923

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Clark, Deborah J. R.
ASSISTANT EXAMINER: Chen, Shin-Lin
LEGAL REPRESENTATIVE: Darby & Darby
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 64 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 1205
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:166378 USPATFULL
TITLE: Minimal adenovirus mediated recombinant vaccine
INVENTOR(S): Fang, Xiangming, San Diego, CA, UNITED STATES
Gallichan, Scott, San Diego, CA, UNITED STATES
Zhang, Wei-Wei, San Diego, CA, UNITED STATES
Wong-Staal, Flossie, San Diego, CA, UNITED STATES
Sauter, Sybille, Del Mar, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002088014	A1	20020704
APPLICATION INFO.:	US 2001-974206	A1	20011010 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-866403, filed on 30 May 1997, PENDING Continuation-in-part of Ser. No. US 1997-791218, filed on 31 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-658961, filed on 31 May 1996, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-239224P	20001010 (60)
	US 2000-241625P	20001019 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 4062
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including, but not limited to, gene vaccination, gene transfer, gene therapy, and the like. More specifically, this invention is related to the Ad vectors that carry the minimal cis-element of the Ad genome (minimal Ad vector) and are capable of delivering about 36 kb to about 38 kb of heterologous DNA. The generation and propagation of the minimal Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line.

This invention further comprises minimal adenoviral vectors for use in the treatment or prevention of disease or other medical conditions, methodologies for generating such vectors and animal test systems for in vivo evaluation of such Ad vectors. More specifically, this invention describes HIV and/or HPV Ad vectors that contain minimal cis-elements of the Ad genome and comprise HIV and/or HPV nucleic acid sequence with other supporting and/or complementing nucleic acid elements up to about 36 kb to about 38 kb. The HIV and/or HPV minimal Ad may be generated and preferentially amplified through the assistance of a packaging-attenuated helper Ad and a helper cell line. This invention also discloses designs and methods for testing such minimal Ad vectors in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:85571 USPATFULL
TITLE: 1-aroyl-piperidinyl benzamidines
INVENTOR(S): Pauls, Heinz, Flemington, NJ, UNITED STATES
Gong, Yong, Bridgewater, NJ, UNITED STATES
Levell, Julian, Summit, NJ, UNITED STATES
Astles, Peter, Kent, UNITED KINGDOM

Eastwood, Paul R., Essex, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045613	A1	20020418
APPLICATION INFO.:	US 2001-841417	A1	20010424 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-18306	20000727
	US 2000-200066P	20000427 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AVENTIS PHARMACEUTICALS, INC., PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807-0800
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 3202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compounds of formula ##STR1##

which inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:27491 USPATFULL
TITLE: Piperididinyl and N-amidinopiperidinyl derivatives
INVENTOR(S): Klein, Scott I., Norristown, PA, UNITED STATES
Guertin, Kevin R., Little Falls, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002016339	A1	20020207
APPLICATION INFO.:	US 2001-922906	A1	20010806 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-273618, filed on 22 Mar 1999, GRANTED, Pat. No. US 6277865		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79002P	19980323 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AVENTIS PHARMACEUTICALS, INC., PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807-0800
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 2328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to a compound of fornula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amnount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2002:22474 USPATFULL
TITLE: Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
INVENTOR(S): Choi-Sledeski, Yong Mi, Collegeville, PA, UNITED STATES
Pauls, Heinz W., Collegeville, PA, UNITED STATES
Barton, Jeffrey N., Philadelphia, PA, UNITED STATES
Ewing, William R., Downingtown, PA, UNITED STATES
Green, Daniel M., Ambler, PANAMA
Becker, Michael R., Norristown, PA, UNITED STATES
Gong, Yong, Norristown, PA, UNITED STATES
Levell, Julian, Royersford, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013310	A1	20020131
APPLICATION INFO.:	US 2001-918039	A1	20010730 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-453307, filed on 2 Dec 1999, GRANTED, Pat. No. US 6281227 Continuation-in-part of Ser. No. WO 1999-US12312, filed on 3 Jun 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-90492, filed on 3 Jun 1998, PENDING Continuation-in-part of Ser. No. WO 1997-US22406, filed on 3 Dec 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33159P	19961213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Synnestvedt & Lechner LLP, 2600 Aramark Tower, 1101 Market Street, Philadelphia, PA, 19107-2950
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 7601
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2001:215074 USPATFULL
TITLE: Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
INVENTOR(S): Klein, Scott I., Norristown, PA, United States
Guertin, Kevin R., Little Falls, NJ, United States
Spada, Alfred P., Lansdale, PA, United States
Pauls, Heinz W., Collegeville, PA, United States
Gong, Yong, Norristown, PA, United States
McGarry, Daniel G., King of Prussia, PA, United States(4)
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Bridgewater, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6323227 B1 20011127
APPLICATION INFO.: US 1999-259528 19990226 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US13550, filed on 26 Jun 1998 Continuation-in-part of Ser. No. US 884405, now patented, Pat. No. US 6080767

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9485P	19960102 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Newman, Irving
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
LINE COUNT: 4683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compounds of formula ##STR1##

which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2001:173361 USPATFULL
TITLE: Process for preparing tissue factor pathway inhibitor
INVENTOR(S): Kamei, Shintaro, Kumamoto, Japan
Kamikubo, Yuichi, Kumamoto, Japan
Hamuro, Tsutomu, Kumamoto, Japan
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Kumamoto-ken, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6300100	B1	20011009
APPLICATION INFO.:	US 1994-266542		19940628 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-188746	19930630

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Eyler, Yvonne
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 673
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In a process for preparing Tissue Factor Pathway Inhibitor (TFPI) by the genetically engineered technique by the use of a transformed animal cell wherein a DNA encoding human TFPI is introduced, the improvement which comprises culturing said transformed animal cell in a culture medium supplemented with a sulfated polysaccharide to protect an intact TFPI produced by said transformed animal cell from cleavage by proteases present in the culture medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:142362 USPATFULL
TITLE: Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
INVENTOR(S): Choi-Sledeski, Yong Mi, Collegeville, PA, United States
Pauls, Heinz W., Collegeville, PA, United States
Barton, Jeffrey N., Philadelphia, PA, United States
Ewing, William R., Downingtown, PA, United States
Green, Daniel M., Ambler, PA, United States
Becker, Michael R., Norristown, PA, United States
Gong, Yong, Norristown, PA, United States
Levell, Julian, Royersford, PA, United States
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6281227	B1	20010828
APPLICATION INFO.:	US 1999-453307		19991202 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1999-US12312, filed on 3 Jun 1999 Continuation-in-part of Ser. No. US 1998-90492, filed on 3 Jun 1998 Continuation-in-part of Ser. No. WO 1997-US22406, filed on 3 Dec 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33159P	19961213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Raymond, Richard L.
ASSISTANT EXAMINER: Truong, Tamthom N.
LEGAL REPRESENTATIVE: Parker, III, Raymond S., Butch, III, Peter J., Newman, Irving
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 7432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2001:139298 USPATFULL
TITLE: Protein complexes having factor VIII:C activity and production thereof
INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States
Burke, Rae Lyn, San Francisco, CA, United States
Rasmussen, Mirella Ezban, Copenhagen, Denmark
Mikkelson, Jan Moller, Gentofte, Denmark
PATENT ASSIGNEE(S): Chiron Corporation and Novo Nordisk A/S (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001016340	A1	20010823
APPLICATION INFO.:	US 2000-748062	A1	20001222 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-441943, filed on 16

May 1995, GRANTED, Pat. No. US 6228620 Division of Ser. No. US 1993-161770, filed on 3 Dec 1993, GRANTED, Pat. No. US 5595886 Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, ABANDONED Continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, ABANDONED Continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 96662-8097
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 1973
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an α.sub.1-antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2001:136668 USPATFULL
TITLE: Piperididinyl and N-amidinopiperidinyl derivatives
INVENTOR(S): Klein, Scott I., Norristown, PA, United States
Guertin, Kevin R., Verona, NJ, United States
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Bridgewater, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6277865	B1	20010821
APPLICATION INFO.:	US 1999-273618		19990322 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-884405, filed on 27 Jun 1997, now patented, Pat. No. US 6080767

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79002P	19980323 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chang, Ceila
LEGAL REPRESENTATIVE: Parker, III, Raymond S., Newman, Irving, Butch, III, Peter J.
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 2335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:67431 USPATFULL

TITLE: Protein complexes having factor VIII:C activity and production thereof

INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States
Burke, Rae Lyn, San Francisco, CA, United States
Rasmussen, Mirella Ezban, Copenhagen, Denmark
Mikkelson, Jan Moller, Gentofte, Denmark

PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228620	B1	20010508
APPLICATION INFO.:	US 1995-441943		19950516 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-161770, filed on 3 Dec 1993, now patented, Pat. No. US 5595886 Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, now abandoned Continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, now abandoned Continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Low, Christopher S. F.

ASSISTANT EXAMINER: Bugaisky, Gabriele E.

LEGAL REPRESENTATIVE: Robins, Roberta L., Guth, Joseph H., Blackburn, Robert P.

NUMBER OF CLAIMS: 91

EXEMPLARY CLAIM: 33

LINE COUNT: 2140

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an α.sub.1 -antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 29 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:51557 USPATFULL

TITLE: Vasoprotective recombinant adenovirus vector containing a human TFPI gene

INVENTOR(S): Zoldhelyi, Pierre, Bellaire, TX, United States
Willerson, James T., Houston, TX, United States

PATENT ASSIGNEE(S): Texas Heart Institute, Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214333	B1	20010410
APPLICATION INFO.:	US 1998-13366		19980126 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51887P	19970708 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Guzo, David
LEGAL REPRESENTATIVE: McDaniel & Associates, P.C., McDaniel, C. Steven, Hall, Elizabeth R.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1537
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A recombinant adenoviral vector encoding the human tissue factor pathway inhibitor (TFPI) gene is disclosed which is useful for transduction of vascular smooth muscle cells at a selected blood vessel site to provide local vascular expression of TFPI. A method of using the transduced hTFPI cDNA as an in vivo antithrombotic agent to provide localized production of hTFPI for protecting an at-risk site against thrombus deposition is also disclosed. Gene therapy using the new TFPI expression vector is also expected to deter the development of chronic vascular stenosis in blood vessels (arteries, veins, arteriovenous shunts, and endovascular grafts) and deterring intimal hyperplasia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2000:146550 USPATFULL
TITLE: Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
INVENTOR(S): Klein, Scott I., Norristown, PA, United States
Guertin, Kevin R., Verona, NJ, United States
Spada, Alfred P., Lansdale, PA, United States
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Bridgewater, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6140504		20001031
APPLICATION INFO.:	US 2000-499335		20000204 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 884405

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9485P	19960102 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Newman, Irving, Butch, Peter
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1,2
LINE COUNT: 2891
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2000:80775 USPATFULL
TITLE: Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
INVENTOR(S): Klein, Scott I., Norristown, PA, United States

Guertin, Kevin R., Little Falls, NJ, United States
Spada, Alfred P., Lansdale, PA, United States
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6080767		20000627
APPLICATION INFO.:	US 1997-884405		19970627 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1996-US20770, filed on 23 Dec 1996

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9485P	19960102 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Oehler, Ross J.
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
LINE COUNT: 3455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds according to the invention are substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides of formula I herein which exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, methods for their preparation and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2000:57741 USPATFULL
TITLE: Protein complexes having Factor VIII:C activity and production thereof
INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States
Burke, Rae Lyn, San Francisco, CA, United States
Rasmussen, Mirella Ezban, Copenhagen, Denmark
Mikkelson, Jan Moller, Gentofte, Denmark
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6060447		20000509
APPLICATION INFO.:	US 1995-441935		19950516 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-266170, filed on 27 Jun 1994, now patented, Pat. No. US 5789203 which is a continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 1996-822989, filed on 27 Jan 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles L.
LEGAL REPRESENTATIVE: Robins, Roberta L., Guth, Joseph H., Blackburn, Robert

P.
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 2096
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an α.sub.1 -antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2000:27989 USPATFULL
TITLE: Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
INVENTOR(S): Ewing, William R., Downingtown, PA, United States
Becker, Michael R., Norristown, PA, United States
Choi-Sledeski, Yong Mi, Collegeville, PA, United States
Pauls, Heinz W., Collegeville, PA, United States
McGarry, Daniel G., King of Prussia, PA, United States
Davis, Roderick S., West Chester, PA, United States
Spada, Alfred P., Lansdale, PA, United States
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6034093		20000307
APPLICATION INFO.:	US 1998-130336		19980806 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1997-US22414, filed on 1 Dec 1997 which is a continuation-in-part of Ser. No. US 1996-761414, filed on 6 Dec 1996, now patented, Pat. No. US 5731315, issued on 24 Mar 1998 which is a continuation-in-part of Ser. No. WO 1996-US9816, filed on 7 Jun 1996 which is a continuation-in-part of Ser. No. US 1995-481024, filed on 7 Jun 1995, now patented, Pat. No. US 5612353, issued on 18 Mar 1997 And a continuation-in-part of Ser. No. WO US9722414 which is a continuation-in-part of Ser. No. US 1997-976034, filed on 21 Nov 1997 which is a continuation of Ser. No. WO US9609816 which is a continuation-in-part of Ser. No. US 481024
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: Oehler, Rose J.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 4980
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions

containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 52 USPATFULL on STN

ACCESSION NUMBER:	1999:117489 USPATFULL
TITLE:	Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminominomethyl)phenylalkyl]-azaheterocyclylamide compounds
INVENTOR(S):	Ewing, William R., Downingtown, PA, United States Becker, Michael R., Norristown, PA, United States Pauls, Henry W., Collegeville, PA, United States Cheney, Daniel L., Collegeville, PA, United States Mason, Jonathan Stephen, Phoenixville, PA, United States Spada, Alfred P., Lansdale, PA, United States Choi-Sledeski, Yong Mi, Collegeville, PA, United States
PATENT ASSIGNEE(S):	Rhone-Poulenc Rorer Pharmaceuticals Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5958918		19990928	
APPLICATION INFO.:	US 1997-976034		19971121	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1996-US9816, filed on 7 Jun 1996 which is a continuation-in-part of Ser. No. US 1995-481024, filed on 7 Jun 1995, now patented, Pat. No. US 5612353			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Davis, Zinna Northington			
LEGAL REPRESENTATIVE:	Parker, III, Raymond S.			
NUMBER OF CLAIMS:	57			
EXEMPLARY CLAIM:	1			
LINE COUNT:	9289			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 52 USPATFULL on STN

ACCESSION NUMBER:	1999:30937 USPATFULL
TITLE:	Factor VIIa inhibitors from Kunitz domain proteins
INVENTOR(S):	Dennis, Mark S., San Carlos, CA, United States Lazarus, Robert A., Milbrae, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5880256		19990309	
APPLICATION INFO.:	US 1995-399115		19950303	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-206310, filed on 4 Mar 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 36 OF 52 USPATFULL on STN
ACCESSION NUMBER: 1999:12902 USPATFULL
TITLE: Factor VIIa inhibitors from kunitz domain proteins
INVENTOR(S): Dennis, Mark S., San Carlos, CA, United States
Lazarus, Robert A., Millbrae, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5863893		19990126
APPLICATION INFO.:	US 1995-398628		19950303 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-206310, filed on 4 Mar 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2603
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 52 USPATFULL on STN
ACCESSION NUMBER: 1998:157308 USPATFULL
TITLE: Pre-formed anticoagulant heparin/TFPI complexes
INVENTOR(S): Wun, Tze-Chein, St. Louis, MO, United States
PATENT ASSIGNEE(S): G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849703		19981215
APPLICATION INFO.:	US 1996-661240		19960610 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-453937, filed on 30 May 1995 which is a continuation-in-part of Ser. No. US 1993-166186, filed on 13 Dec 1993, now abandoned

which is a continuation of Ser. No. US 1990-573083, filed on 27 Aug 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Sayala, Chhaya D.
LEGAL REPRESENTATIVE: Meyer, Scott J.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 798
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pre-formed anticoagulant heparin/TFPI complex which consists of a weight ratio of at least 1.25 parts of heparin to one part of TFPI and its use in inhibiting blood cogulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 38 OF 52 USPATFULL on STN
ACCESSION NUMBER: 1998:138687 USPATFULL
TITLE: Factor VIIa inhibitors from Kunitz domain proteins
INVENTOR(S): Dennis, Mark S., San Carlos, CA, United States
Lazarus, Robert A., Millbrae, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5834244		19981110	
APPLICATION INFO.:	US 1995-398010		19950303	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-206310, filed on 4 Mar 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2676
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 52 USPATFULL on STN
ACCESSION NUMBER: 1998:135168 USPATFULL
TITLE: Process for purifying factor VIII
INVENTOR(S): Almstedt, Annelie, Sp.ang.nga, Sweden
Sandberg, Helena, Bromma, Sweden
Smeds, Anna-Lisa, Sollentuna, Sweden
Wrangel, Maria, Vallingby, Sweden
Ostlin, Anna, Stockholm, Sweden
PATENT ASSIGNEE(S): Pharmacia & Upjohn AB, Stockholm, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5831026		19981103	
	WO 9615150		19960523	
APPLICATION INFO.:	US 1997-809756		19970530	(8)

WO 1995-SE1351 19951114
19970530 PCT 371 date
19970530 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1994-3915	19941114

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Mohamed, Abdel A.
LEGAL REPRESENTATIVE: Dinsmore & Shohl LLP
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for reducing degradation of recombinant coagulation factor VIII caused by metal-dependent proteases requiring Zn.sup.2+ for activity or containing Zn.sup.2+ as an integral part of their structure comprises adding an inhibitor of Zn.sup.2+ dependent proteases to a recombinant factor VIII solution. The recombinant factor VIII solution is obtained after harvesting a conditioned medium from a cell culture used for producing the recombinant coagulation factor VIII. The inhibitor is selected from complexing agents with a stronger affinity for the Zn.sup.2+ ion of the protease than for the ion or ions stabilizing the factor VIII molecule, and compounds structurally related to the natural substrate of the protease and containing an electronegative moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 40 OF 52 USPATFULL on STN
ACCESSION NUMBER: 1998:98974 USPATFULL
TITLE: Factor VIIa inhibitors from Kunitz domain proteins
INVENTOR(S): Lazarus, Robert A., Milbrae, CA, United States
Dennis, Mark S., San Carlos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5795954		19980818	
APPLICATION INFO.:	US 1994-206310		19940304	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2051
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, and plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 52 USPATFULL on STN
ACCESSION NUMBER: 1998:91834 USPATFULL
TITLE: Protein complexes having factor VIII:C activity and production thereof

INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States
Burke, Rae Lyn, San Francisco, CA, United States
Rasmussen, Mirella Ezban, Copenhagen, Denmark
Mikkelson, Jan Moller, Gentofte, Denmark
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789203		19980804
APPLICATION INFO.:	US 1994-266170		19940627 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Barovsky, Kenneth, Robins, Roberta, Blackburn, Robert P.
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 1898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an α.sub.1 -antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 52 USPATFULL on STN
ACCESSION NUMBER: 1998:31022 USPATFULL
TITLE: Substituted sulfonic acid n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds
INVENTOR(S): Ewing, William R., Downingtown, PA, United States
Becker, Michael R., Norristown, PA, United States
Choi-Sledeski, Yong Mi, Collegeville, PA, United States
Pauls, Heinz W., Collegeville, PA, United States
McGarry, Daniel G., King of Prussia, PA, United States
Davis, Roderick S., West Chester, PA, United States
Spada, Alfred P., Lansdale, PA, United States
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5731315		19980324
APPLICATION INFO.:	US 1996-761414		19961206 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-481024, filed on 7 Jun 1995, now patented, Pat. No. US 5612353
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Northington-Davis, Zinna
LEGAL REPRESENTATIVE: Parker, III, Raymond S., Savitzky, Martin F.
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
LINE COUNT: 3981
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 43 OF 52 USPATFULL on STN
ACCESSION NUMBER: 97:63992 USPATFULL
TITLE: Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
INVENTOR(S): Schwartz, Alan L., Clayton, MO, United States
Warshawsky, Ilka, St. Louis, MO, United States
Broze, George J., Ladue, MO, United States
PATENT ASSIGNEE(S): Jewish Hospital of St. Louis, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5650391		19970722
APPLICATION INFO.:	US 1994-216593		19940321 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Allen, Marianne P.
ASSISTANT EXAMINER: Gucker, Stephen
LEGAL REPRESENTATIVE: Bennett, Dennis A.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 788
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses methods and compositions for inhibiting the hepatic clearance of Tissue Factor Pathway Inhibitor (TFPI) using receptor-associated protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 44 OF 52 USPATFULL on STN
ACCESSION NUMBER: 97:33783 USPATFULL
TITLE: Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
INVENTOR(S): Worsaae, Helle, Gentofte, Denmark
Rasmussen, Frank W., Valby, Denmark
Rasmussen, Mirella E., Copenhagen, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5622988		19970422
APPLICATION INFO.:	US 1995-405336		19950316 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-95785, filed on 22 Jul 1993, now patented, Pat. No. US 5409951 which

is a continuation-in-part of Ser. No. US 1991-714107, filed on 11 Jun 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1990-1461	19900615

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Nicky
LEGAL REPRESENTATIVE: Zelson, Esq., Zelson T., Agris, Esq., Cheryl H.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of compounds of formula I ##STR1## wherein R.sup.1 is independently hydrogen, hydroxy, alkyl with 1 to 6 carbon atoms, acyloxy groups with 1 to 6 carbon atoms, alkyloxy with 1 to 6 carbon atoms or from 1 to 5 sugar moieties; and R.sup.2 is independently hydrogen, or alkyl with 1 to 6 carbon atoms, in the reduction of coagulation time in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 52 USPATFULL on STN
ACCESSION NUMBER: 97:20645 USPATFULL
TITLE: Process for producing a coagulation active complex of factor VIII fragments
INVENTOR(S): Nordfang, Ole, Hiller.o slashed.d, Denmark
Rasmussen, Mirella E., Copenhagen, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5610278		19970311
APPLICATION INFO.:	US 1995-383034		19950203 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-65702, filed on 21 May 1993 which is a continuation of Ser. No. US 1992-869885, filed on 14 Apr 1992, now abandoned which is a continuation of Ser. No. US 1989-298465, filed on 18 Jan 1989, now abandoned which is a division of Ser. No. US 1988-162323, filed on 23 Feb 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-932923, filed on 19 Nov 1986, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1986-2957	19860624

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Argis, Esq., Cheryl H.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A coagulation active complex of Factor VIII fragments is produced by causing coagulation inactive FVIII heavy chain to react with coagulation inactive FVIII light chain in the presence of a complex forming agent. Thus, FVIII-HC and FVIII-LC are converted to coagulation active FVIII complex in the presence of divalent metal ions, such as Mn.sup.2+, Ca.sup.2+ or C.sup.2+, or a component of the pro-thrombin complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 52 USPATFULL on STN

ACCESSION NUMBER:	97:20404 USPATFULL
TITLE:	Method of producing proteins with FVIII activity and/or FVIII derivatives
INVENTOR(S):	Rasmussen, Poul B., Hellerup, Denmark Nordfang, Ole, Hillerod, Denmark
PATENT ASSIGNEE(S):	Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5610033		19970311
APPLICATION INFO.:	US 1994-320773		19941011 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-877347, filed on 30 Apr 1992, now abandoned which is a continuation of Ser. No. US 1990-514072, filed on 25 Apr 1990, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Ziska, Suzanne E.
LEGAL REPRESENTATIVE:	Zelson, Esq., Steve T., Agris, Esq., Cheryl H.
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT:	289

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for producing proteins with FVIII activity and FVIII derivatives by in vitro culturing of mammalian cells, the culturing is carried out at temperatures below 32° C. and the culturing times used are below 24 hours.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 47 OF 52 USPATFULL on STN

ACCESSION NUMBER:	97:5867 USPATFULL
TITLE:	Protein complexes having Factor VIII:C activity and production thereof
INVENTOR(S):	Chapman, Barbara, Berkeley, CA, United States Burke, Rae L., San Francisco, CA, United States
PATENT ASSIGNEE(S):	Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5595886		19970121
APPLICATION INFO.:	US 1993-161770		19931203 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Jacobson, Dian C.
LEGAL REPRESENTATIVE:	Reed & Robins, Blackburn, Robert P.
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
LINE COUNT:	1532

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB DNA constructs encoding human Factor VIII:C protein are disclosed. In particular, the DNA construct contains a nucleotide sequence that encodes a first polypeptide homologous to the A domain of human Factor

VIII:C linked to a second polypeptide homologous to the C domain of human Factor VIII:C by a polypeptide spacer that comprises a peptide homologous to a human Ig heavy chain hinge region. Recombinant methods for producing human Factor VIII:C protein are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 48 OF 52 USPATFULL on STN

ACCESSION NUMBER:	96:106467 USPATFULL
TITLE:	Human Kunitz-type protease inhibitor variant
INVENTOR(S):	Norris, Fanny, Hellerup, Denmark Norris, Kjeld, Hellerup, Denmark Bj.o slashed.rn, S.o slashed.ren E., Lyngby, Denmark Petersen, Lars C., H.o slashed.rsholm, Denmark Olsen, Ole H., Br.o slashed.nsh.o slashed.j, Denmark
PATENT ASSIGNEE(S):	Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5576294		19961119
APPLICATION INFO.:	US 1994-321658		19941012 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-21610, filed on 22 Feb 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1992-DK1	19920107

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Wax, Robert A.
ASSISTANT EXAMINER:	Kim, Hyosuk
LEGAL REPRESENTATIVE:	Zelson, Steve T., Lambiris, Elias J.
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT:	1204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Variant of human Kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI), the variant comprising the following amino acid sequence ##STR1## wherein Xaa at position 1 is H or a naturally occurring amino acid residue except Cys, each Xaa at positions 2-5 is independently a naturally occurring amino acid residue except Cys or is absent, each Xaa at positions 14, 16, 18, 19, 20, 21, 22, 23, 37, 42, 43, 44, and 49 independently a naturally occurring amino acid except Cys, each Xaa at positions 61, 62, 63, and 64 is independently a naturally occurring amino acid except Cys or is absent, and Xaa at position 65 is OH or a naturally occurring amino acid except Cys, with the proviso that at least one of the amino acid residues designated Xaa is different from the amino acid residue of the native sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 49 OF 52 USPATFULL on STN

ACCESSION NUMBER:	96:70540 USPATFULL
TITLE:	Process for producing a coagulation active complex of factor VIII fragments
INVENTOR(S):	Nordfang, Ole, Hillerod, Denmark Rasmussen, Mirella E., Copenhagen, Denmark
PATENT ASSIGNEE(S):	Novo Nordisk A/S, Novo Alle, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5543502 19960806
APPLICATION INFO.: US 1995-383541 19950203 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-92658, filed on 14 Jul 1993, now abandoned which is a continuation of Ser. No. US 1992-956445, filed on 2 Oct 1992, now abandoned which is a continuation of Ser. No. US 1992-835100, filed on 11 Feb 1992, now abandoned which is a continuation of Ser. No. US 1988-162323, filed on 23 Feb 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-932923, filed on 19 Nov 1986, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1986-2957	19860624

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Degen, Nancy J.
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Agris, Esq., Cheryl H.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A coagulation active complex of Factor VIII fragments is produced by causing a coagulation inactive FVIII heavy chain to react with a coagulation inactive FVIII light chain in the presence of a complex forming agent. Thus, FVIII-HC and FVIII-LC are converted to coagulation active FVIII complex in the presence of metal ions, such as Mn.sup.2+, Ca.sup.2+, or Co.sup.2+ or a component of the prothrombin complex or a substance having reactivity to compounds containing the group --SH and/or --S--S.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 50 OF 52 USPATFULL on STN
ACCESSION NUMBER: 95:1518 USPATFULL
TITLE: Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
INVENTOR(S): Petersen, Jens G. L., Valby, Denmark
Nordfang, Ole J., Hilleroed, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5378614		19950103
APPLICATION INFO.:	US 1993-26145		19930302 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-828920, filed on 27 Jan 1992, now patented, Pat. No. US 5312736

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1989-4080	19890818

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Fitzgerald, David L.
LEGAL REPRESENTATIVE: Zelson, Steve T., Lowney, Karen A.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for making TFPI analogues lacking part of the C-terminal end of the native TFPI molecule is described by cultivation of a yeast strain transformed with an expression vector containing a DNA sequence encoding such TFPI analogues. The TFPI analogues will at least contain the two first Kunitz domains and lack the third Kunitz domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 52 USPATFULL on STN
ACCESSION NUMBER: 89:39058 USPATFULL
TITLE: Preparation for the treatment of hemophilia A inhibitor patients and a process for producing such a preparation
INVENTOR(S): Nordfang, Ole, Selskovvej 6, DK-3400 Hillerod, Denmark
Rasmussen, Mirella E., Abildgaardsgade 24, DK-2100 Copenhagen 0, Denmark

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4831119		19890516	
	WO 8602838		19860522	
APPLICATION INFO.:	US 1986-881687		19860620	(6)
	WO 1985-DK105		19851105	
			19860620	PCT 371 date
			19860620	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1984-5253	19841105

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Welsh, Maurice J.
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Ladas & Parry
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A preparation for the treatment of hemophilia A inhibitor patients contains a protein or peptide having a specific Factor VIII:CAg activity of at least 0.5, preferably at least 1 VIII:CAg unit per mg protein, the ratio between the VIII:CAg activity and the VIII:C procoagulant activity being greater than 5:1, preferably greater than 10:1. A fragment of Factor VI-II:C, which displays a doublet of a molecular weight of 80/77 kD in electrophoresis, is reactive hemophilia A inhibitor antibodies and has VIII:CAg activity. This fragment and more low-molecular fragments of Factor VIII:C are capable of neutralizing the coagulation inhibiting effect of all tested antibodies. Such fragments can therefore be used as active component in preparations for providing immunotolerance towards Factor VIII:C in high-dose treatment of inhibitor patients. The peptides are moreover useful as an immunosorbent in specific extracorporeal adsorption treatment of inhibitor patients. The inhibitor reactive peptides can e.g. be recovered from plasma fractions by affinity chromatography, hydrophobic interaction chromatography or cation exchange or they may be biosynthetically and recovered in a similar manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 52 USPAT2 on STN
ACCESSION NUMBER: 2002:338043 USPAT2
TITLE: Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
INVENTOR(S): Burns, Christopher J., Malvern, PA, United States

Dankulich, William P., Collegeville, PA, United States
McGarry, Daniel G., Bedminister, NJ, United States
Volz, Francis A., Neshanic Station, NJ, United States
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., Bridgewater, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6599918	B2	20030729
APPLICATION INFO.:	US 2002-81113		20020222 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-IB1562, filed on 12 Aug 2000

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-24155	19991012
	US 1999-150767P	19990826 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Solola, Taofiq
LEGAL REPRESENTATIVE: Parker, III, Raymond S.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>